Ethanol, 2-[[4-[(3-ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]oxy]-, hydrochloride (1:1)
| Title | Journal |
|---|---|
| Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. | Clinical lung cancer 20110901 |
| Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110715 |
| Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110101 |
| Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701 |
| Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100501 |
| Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. | Cancer chemotherapy and pharmacology 20080901 |
| The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. | Cancer chemotherapy and pharmacology 20080801 |
| Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. | British journal of cancer 20080520 |
| Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. | Anti-cancer drugs 20080201 |
| The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401 |
| Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070301 |
| Effects of smoking on the pharmacokinetics of erlotinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060401 |
| Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. | Journal of clinical pharmacology 20060301 |
| Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050105 |
| Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030815 |